Search

September 19, 2016 - Drug therapy with beta blockers represents the therapeutic mainstay for both LQTS and CPVT. Our goal is to help clinicians understand the importance of beta blocker therapy in these two genetic disorders, as well as to provide clinical guidance on the choice of agents. Nadolol, when available, has been the preferred beta blocker utilized by the largest LQTS/CPVT specialty centers throughout the world for the past 25 years.

May 5, 2011 (Updated August 1, 2011) – Genetic testing is increasingly important in determining potential cardiac conditions in patients and is used in clinical settings more than ever before. To ensure that physicians have up-to-date knowledge of the evolving role of genetic testing for sudden death predisposing, genetic heart diseases in cardiology, which can be life-saving for some patients, the Heart Rhythm Society and the European Heart Rhythm Association have prepared HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. The consensus statement was released at Heart Rhythm 2011, the Heart Rhythm Society’s 32nd Annual Scientific Sessions.